HONG KONG–(BUSINESS WIRE)–Aptorum Group Limited (Nasdaq: APM) (“Aptorum”) announced today, the
appointment of Dr. Thomas Wai-yip Lee as Head of Research and
Development (“Head of R&D”) and Dr. Angel Siu-yan Ng as Chief Operating
Officer (“COO”) of Aptorum, effective on April 1, 2019.
Dr. Thomas Lee joined Aptorum in January 2018 as the Chief Executive
Officer and Chief Scientific Officer of Aptorum Therapeutics Limited, a
wholly-owned subsidiary of Aptorum. Before joining Aptorum, Dr. Lee was
an Assistant Professor at the School of Pharmacy at The Chinese
University of Hong Kong. His key area of research involves drug delivery
with specialties on formulation development of poorly soluble compounds,
oral delivery, nanotechnology, and similar fields. Prior to academia,
Dr. Lee accumulated big-pharma experience from spending a decade at two
global pharmaceutical companies in the U.S.
Dr. Angel Ng joined Aptorum in September 2017 as Chief Operating Officer
of Aptorum Therapeutics Limited. Dr. Ng leads Aptorum and its subsidiary
companies’ operations and business strategies. Dr. Ng has extensive
experience in project management with Innovation and Technology
government funds and academic institutions. She also worked on
technology transfer and commercialization for research and development
projects.
At the same time, Dr. Keith Kwei-hang Chan, Chief Scientific Officer
(“CSO”) of Aptorum, will transition to serve as a key member of our
newly formed Scientific Advisory Board, effective on April 1, 2019.
“I am pleased to announce the expansion of our management team. Dr. Lee
has gained solid research and development experience from academia and
big pharma, and Dr. Ng has extensive experience in operations and
project management. Their expertise and experience will be most
invaluable in advancing Aptorum’s pipeline.” said Mr. Ian Huen, the
Founder, Executive Director and Chief Executive Officer of Aptorum. “We
also thank Dr. Chan for his significant contributions to Aptorum during
his term as CSO, and for his continuous support to Aptorum’s development
by serving on the Scientific Advisory Board.”
About Aptorum Group Limited
We are a Hong Kong based pharmaceutical company currently in the
preclinical stage, dedicated to developing and commercializing a broad
range of therapeutic and diagnostic technologies to tackle unmet medical
needs. We are pursuing therapeutic and diagnostic projects in neurology,
infectious diseases, gastroenterology, oncology and other disease areas.
We also have projects focused on non-therapeutic area such as surgical
robotics as well as the operations of our medical clinic in Hong Kong,
Talem Medical, with the initial focus on treatment of chronic diseases
resulting from modern sedentary lifestyles and aging population.
For more information about the Company, please visit www.aptorumgroup.com.
Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited
and its future expectations, plans and prospects that constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. For this purpose, any
statements contained herein that are not statements of historical fact
may be deemed to be forward-looking statements. In some cases, you can
identify forward-looking statements by terms such as “may,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “target,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential,” or “continue,” or the negative of these terms or other
similar expressions. Aptorum has based these forward-looking statements
largely on its current expectations and projections about future events
and trends that it believes may affect its business, financial condition
and results of operations. These forward-looking statements speak only
as of the date of this press release and are subject to a number of
risks, uncertainties and assumptions including, without limitation,
risks related to its announced management and organizational changes,
the continued service and availability of key personnel, its ability to
expand its product assortments by offering additional products for
additional consumer segments, the company’s anticipated growth
strategies, anticipated trends and challenges in its business, and its
expectations regarding, and the stability of, its supply chain, and the
risks more fully described in Aptorum’s Prospectus (File No. 333-227198)
filed with the U.S. Securities and Exchange Commission (the “SEC”) on
December 4, 2018 and other filings that Aptorum may make with the SEC in
the future. Aptorum assumes no obligation to update any forward-looking
statements contained in this press release as a result of new
information, future events or otherwise.
Contacts
Investor relations:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Media:
Tel:
+ 852 2117 6611
Email: info@aptorumgroup.com